and new pacemaker after implantation of the balloon-expandable Sapien prosthesis (BES). Methods: We analyzed 252 consecutive patients undergoing implantation of BES without pre-existing pacemaker. All patients underwent pre-procedural CT assessment of the aortic root. The congruence between annulus and valve prosthesis was assessed using the area cover index (ACI): 100 x (prosthesis area -CT annulus area/ prosthesis area). ECGs were performed at baseline, immediately after TAVI and at discharge. Results: We divided the population in two groups according to median ACI value. There were no differences in baseline characteristics except more women in the ACI !17% group compared to ACI < 17% group (67% vs. 33% p< 0.01). The QRS interval duration immediately after TAVI and at discharge, incidence of new LBBB and of new pacemaker was significantly higher in ACI !17% group (Figure) .
Background: Encouraging results have been demonstrated for TAVI in patients with reduced left ventricular (LV) ejection fraction (LVEF) . Not all patients with systolic LV dysfunction may profit from TAVI to the same extent, however. The largest benefit is typically observed in patients who demonstrate LV function (LVF) recovery after valve intervention. Aim of this study was to identify predictors of LVF recovery (absolute increase in LVEF of !10%) at mid-term follow-up after TAVI in patients with preoperative moderate to severe LV dysfunction (LVEF 40%). Methods: Six international TAVI centers participated in this multicenter retrospective registry. All patients with LVEF 40% who underwent TAVI for symptomatic severe aortic valve stenosis (AS) were identified in local institutional databases. Baseline, procedural and follow-up clinical data and echocardiographic images were reviewed for relevant data. Results: Between November 2005 and July 2013, 1497 patients underwent TAVI for symptomatic AS, of which 253 (17%) had a LVEF 40%. Eventually, 150 (60%) patients (mean age 78.6AE8.2 years, 62% male) were included in the study, as 103 (40%) patients lacked echocardiographic mid-term follow-up or underwent interfering resynchronization therapy. There were no significant baseline differences between included and excluded patients. TAVI was mainly performed through transfemoral (85%) or transapical (11%) approach with an Edwards SAPIEN (37%) or Medtronic CoreValve (63%) device. At mid-term follow-up, 67 (45%) patients demonstrated LVF improvement. Previous CABG (OR¼0.21, CI 95% 0.07-0.60, p¼0.004), absence of concentric remodeling (OR¼0.35, CI 95% 0.15-0.84, p¼0.019) and preoperative left bundle branch block (OR¼0.35, CI 95% 0.13-0.98, p¼0.047) were independently associated with a reduced likelihood of LVF improvement; higher preoperative mean gradient (OR¼1.04, CI 95% 1.01-1.07, p¼0.018) with an increased likelihood of LVF improvement. Conclusions: Previous CABG, absence of concentric remodeling, and preoperative LBBB are negatively associated, while higher mean gradient is positively associated with LVF improvement after TAVI in patients with preoperative moderate to severe LV dysfunction.
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